What is Bevacizumab Biosimilar? (Treatment Overview)
Bevacizumab Biosimilar 100mg / 400mg Injection is a monoclonal antibody anti-VEGF (Vascular Endothelial Growth Factor) therapy widely used in modern oncology treatment protocols.
It works by blocking VEGF proteins, which helps in:
Preventing tumor blood vessel formation (angiogenesis)
Slowing cancer growth and progression
Improving response rates in combination chemotherapy
Key Therapeutic Indications
Bevacizumab biosimilar is commonly used in the treatment of:
Colorectal cancer
Non-small cell lung cancer (NSCLC)
Kidney (renal cell) carcinoma
Cervical cancer
Ovarian cancer
Glioblastoma (brain tumor)
Available Strengths
Bevacizumab Biosimilar 100mg Injection
Bevacizumab Biosimilar 400mg Injection
Both formulations are used in hospital oncology protocols depending on patient dosage requirements.
Global Export Supply from India
India is a leading hub for WHO-GMP certified biosimilar manufacturing and oncology injectables export.
Cordium Pharmaceuticals Pvt Ltd supplies Bevacizumab biosimilar formulations with regulated quality standards, cold-chain handling, and export documentation support.
Fast Export Delivery Countries
We supply Bevacizumab Biosimilar injection to global markets including:
🌍 Africa
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇿🇦 South Africa
🌏 Asia
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 UAE
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🌎 Western Markets
🇺🇸 USA
🇬🇧 UK
Why Choose Indian Bevacizumab Biosimilars?
India is globally recognized for cost-effective oncology biosimilars with international compliance.
Key Advantages:
WHO-GMP certified manufacturing
Cost-effective compared to originator biologics
High-quality biosimilar equivalence
Stable supply chain for hospitals & distributors
Export-ready documentation support
Cold chain packaging & logistics safety
Clinical Importance of Anti-VEGF Therapy
Bevacizumab targets angiogenesis pathways, making it a cornerstone in:
Advanced-stage cancer management
Combination chemotherapy regimens
Metastatic cancer control
Tumor progression delay strategies
Export & Supply Capability
Cordium Pharmaceuticals Pvt Ltd ensures:
Bulk hospital supply
Government tender support
International distributor partnerships
Fast dispatch and air cargo shipping
Regulatory documentation (COA, MSDS, etc.)
Conclusion
Bevacizumab Biosimilar 100mg / 400mg Injection is a critical targeted oncology therapy used worldwide for advanced cancer treatment protocols. With strong manufacturing capabilities and global logistics support, India continues to be a key supplier of biosimilar medicines.
Cordium Pharmaceuticals Pvt Ltd delivers reliable, quality-assured, and fast-export oncology injectables to hospitals, distributors, and healthcare institutions across Africa, Asia, and Western markets.
Bevacizumab Biosimilar 100mg / 400mg Injection is a monoclonal antibody anti-VEGF (Vascular Endothelial Growth Factor) therapy widely used in modern oncology treatment protocols.
It works by blocking VEGF proteins, which helps in:
Preventing tumor blood vessel formation (angiogenesis)
Slowing cancer growth and progression
Improving response rates in combination chemotherapy
Key Therapeutic Indications
Bevacizumab biosimilar is commonly used in the treatment of:
Colorectal cancer
Non-small cell lung cancer (NSCLC)
Kidney (renal cell) carcinoma
Cervical cancer
Ovarian cancer
Glioblastoma (brain tumor)
Available Strengths
Bevacizumab Biosimilar 100mg Injection
Bevacizumab Biosimilar 400mg Injection
Both formulations are used in hospital oncology protocols depending on patient dosage requirements.
Global Export Supply from India
India is a leading hub for WHO-GMP certified biosimilar manufacturing and oncology injectables export.
Cordium Pharmaceuticals Pvt Ltd supplies Bevacizumab biosimilar formulations with regulated quality standards, cold-chain handling, and export documentation support.
Fast Export Delivery Countries
We supply Bevacizumab Biosimilar injection to global markets including:
🌍 Africa
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇿🇦 South Africa
🌏 Asia
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 UAE
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🌎 Western Markets
🇺🇸 USA
🇬🇧 UK
Why Choose Indian Bevacizumab Biosimilars?
India is globally recognized for cost-effective oncology biosimilars with international compliance.
Key Advantages:
WHO-GMP certified manufacturing
Cost-effective compared to originator biologics
High-quality biosimilar equivalence
Stable supply chain for hospitals & distributors
Export-ready documentation support
Cold chain packaging & logistics safety
Clinical Importance of Anti-VEGF Therapy
Bevacizumab targets angiogenesis pathways, making it a cornerstone in:
Advanced-stage cancer management
Combination chemotherapy regimens
Metastatic cancer control
Tumor progression delay strategies
Export & Supply Capability
Cordium Pharmaceuticals Pvt Ltd ensures:
Bulk hospital supply
Government tender support
International distributor partnerships
Fast dispatch and air cargo shipping
Regulatory documentation (COA, MSDS, etc.)
Conclusion
Bevacizumab Biosimilar 100mg / 400mg Injection is a critical targeted oncology therapy used worldwide for advanced cancer treatment protocols. With strong manufacturing capabilities and global logistics support, India continues to be a key supplier of biosimilar medicines.
Cordium Pharmaceuticals Pvt Ltd delivers reliable, quality-assured, and fast-export oncology injectables to hospitals, distributors, and healthcare institutions across Africa, Asia, and Western markets.
Keywords
